SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 24, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that the
first module of its modular premarket approval
application (PMA) submission for the Diasensor 2000 was
submitted to the FDA. The Diasensor 2000 noninvasive
glucose monitor is similar to the Diasensor 1000 model
with enhancements to the operating software and
hardware.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 24, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL SUBMITS MODULE FOR DIASENSOR TO FDA
Pittsburgh, PA - May 24, 1999 - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that the first module of its modular
premarket approval application (PMA) submission for the Diasensor
2000 was submitted to the FDA. This module contains a
description of Biocontrol Technology's manufacturing methods,
facilities and controls, including design controls as required by
FDA regulations. The FDA approved Biocontrol's PMA Shell
submission in mid April of this year.
The Diasensor 2000 noninvasive glucose monitor is similar
to the Diasensor 1000 model with enhancements to the operating
software and hardware.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Biocontrol has
the exclusive rights to the research and development and
manufacturing of the Diasensor 2000. Subsidiary Diasensor.com,
Inc., also located in Pittsburgh, PA, owns the patent, marketing
and distribution rights to the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
